KCT0007964已完成未知
A 24 week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of BLH308 on Health of Hair
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 60(Year)（—）
- 性别
- All
入选标准
- •1) Man and woman over the age of 19 and under the age of 60
- •2) Glossy scores according to the visual evaluation classification method correspond to 1 point or more and 3 points or less and a total hair damage score of less than 18 points evaluated according to exposure to risk factors
- •3) A person capable of maintaining the same hair shape and color during this human body application test
- •4) A person who agrees to participate in the human body application test and prepares a written consent form prior to the commencement of the human body application test
排除标准
- •1) A person currently being treated for infectious diseases and malignant tumors, including severe cardiovascular system, immune system, respiratory system, hepatometer, kidney and urology system, nervous system, musculoskeletal system, psychosis, skin, etc
- •2) As of Visit 1, those who currently have dull dermatitis, scalp psoriasis, and scalp infection
- •3) A person who has other hair loss diseases, such as circular alopecia, resting alopecia, and scarlet alopecia, in addition to androgen alopecia
- •4) A person who plans to manage and operate hair supplies, hair products during this human body application test
- •5) A person who has received surgical treatment, such as hair transplantation and scalp reduction, within one year as of Visit 1
- •6) A person who has applied topical hair growth agents, wool, and hair growth agents for the last 1 month (30 days) or more as of Visit 1
- •7) A person who has applied topical steroids to the scalp for the last 1 month (30 days) or more as of Visit 1
- •8) Those who have been administered systemic steroids, cell death agents, vasodilators, antihypertensive agents, antiepileptic agents, beta receptor blockers, bronchodilators, diuretics, Cimetidine, Diazoxide, Cyclosporine, and Ketoconazole for the last 1 month or more (30 days)
- •9) A person who has taken oral Dutasteride or Finasteride within 6 months of visit 1
- •10) Patients with uncontrolled hypertension (as measured after stabilizing for 10 minutes with systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 100 mmHg or more)
- •11) Uncontrolled diabetics (above 180 mg/dL of fasting blood sugar)
- •12) Those with 2.4 mg/dL or more of creatine
- •13) Those with an AST (GOT) or ALT (GPT) of 120 IU/L or more
- •14) Those with a TSH of 0.1 µIU/mL or 10 µIU/mL or more
- •15) A person who has a problem with food intake for human body application tests due to severe gastrointestinal disorders
- •16) A person who has participated in other interventional clinical trials (including human application tests) within one month (30 days) of visit 1 or plans to participate in other interventional clinical trials (including human application tests) after the start of this human application test
- •17) A person who is pregnant or who has a plan to become pregnant during the nursing mother or during this human body application test
- •18) A person who is sensitive to or allergic to food ingredients for this human body application test;
- •19) A person who is deemed inappropriate by the tester for other reasons
研究者
相似试验
进行中（未招募）
不适用
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease. - N/AChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 13.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-023349-32-GRGlaxoSmithKline Research & Development Ltd1,463
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Three Different Medicines to Treat COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 13.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-023348-33-SEGlaxoSmithKline Research & Development Ltd1,463
进行中（未招募）
不适用
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease. - N/AChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2010-023348-33-HUGlaxoSmithKline Research & Development Ltd1,463
进行中（未招募）
不适用
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease. - N/AChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2010-023348-33-EEGlaxoSmithKline Research & Development Ltd1,463
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Three Different Medicines to Treat COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-023348-33-DKGlaxoSmithKline Research & Development Ltd1,463